Evidence map›Paper›PMID 36348408›Full record

ArticleEuropean journal of medical research2022

NKD2 is correlated with the occurrence, progression and prognosis of thyroid carcinoma.

Yu Gao, Yiwei Wang, Rende Guo

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Younger Than 55 Years Old andInternational journal of general medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yu GaoDepartment of General Surgery, Tianjin First Center Hospital, No. 94 Fukang Road, Nankai District, Tianjin, 300192, China.
Yiwei WangDepartment of General Surgery, Tianjin First Center Hospital, No. 94 Fukang Road, Nankai District, Tianjin, 300192, China.
Rende GuoDepartment of General Surgery, Tianjin First Center Hospital, No. 94 Fukang Road, Nankai District, Tianjin, 300192, China. TJGuord@outlook.com.
Tianjin Medical University · CNTianjin First Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid carcinoma (THCA) is the most prevalent type of tumor in endocrine system. NKD2 has been increasingly evidenced to play crucial roles in many cancers, except for THCA. We herein aimed to explore the potential role of NKD2 in THCA.

methodsTotally 502 THCA patient data were downloaded from TCGA (The Cancer Genome Atlas) database. Overall survival was estimated by Kaplan-Meier method. Gene set enrichment analysis was conducted to obtain significant functional pathways. Wilcoxon rank sum test was used to determine the NKD2 expression differences among various groups. The NKD2 expression was validated in cell lines and tissue microarray.

resultsSignificantly higher NKD2 expression was observed in THCA samples compared with adjacent samples, which were successfully verified in cell lines and tissue microarray. Moreover, NKD2 expression gradually elevated along with the increase of TNM Stage, and NKD2 expression was significantly higher in elder THCA patients compared with young patients. NKD2 highly expressed THCA patients had worse prognosis compared with NKD2 low-expressed patients. Furthermore, 53 pathways were significantly activated in the high NKD2 expression patients compared with low NKD2 expression THCA patients.

conclusionsIn summary, high NKD2 expression was probably related to the progression and poor prognosis of THCA. NKD2 is a promising prognostic biomarker and pathogenic target of THCA.

Indexed as

Carrier ProteinsThyroid NeoplasmsAdaptor Proteins, Signal TransducingAgedCalcium-Binding ProteinsHumansPrognosisAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsCarrier ProteinsNKD2 protein, humanNKD2PrognosisProgressionRT-PCRThyroid carcinoma

Identifiers

PMID36348408
PMCPMC9641892
OpenAlexW4308589990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.